CervoMed Inc. (NASDAQ: CRVO) is recognized as one of the best-performing NASDAQ stocks by analysts. Dr. Marco Verwijs joins as Executive Vice President, Technical Operations to advance neflamapimod through Phase 3 testing. Neflamapimod is a small-molecule brain penetrant targeting synaptic dysfunction in neurodegenerative disorders like DLB.

CervoMed Inc. (NASDAQ: CRVO) is a clinical-stage biotechnology company focusing on treatments for age-related neurologic disorders. Dr. Verwijs’s expertise in drug development and commercialization will bolster the company’s Chemistry, Manufacturing, and Controls division.

Neflamapimod, an investigational drug by CervoMed, targets p38 mitogen-activated protein kinase alpha to potentially reverse synaptic dysfunction in neurodegenerative disorders. The company’s research focuses on developing treatments for age-related neurologic disorders like DLB.

CervoMed’s strategic hire of Dr. Verwijs as Executive VP, Technical Operations aims to advance neflamapimod through Phase 3 testing. Neflamapimod is a promising treatment for neurodegenerative disorders, targeting synaptic dysfunction in conditions like DLB.

CervoMed Inc. (NASDAQ: CRVO) is a leading biotechnology company specializing in treatments for age-related neurologic disorders. Dr. Verwijs’s appointment as Executive VP, Technical Operations underscores the company’s commitment to advancing neflamapimod through Phase 3 testing.

Read more at Yahoo Finance: CervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3